One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Nkarta logo
Nkarta NKTX
$ 1.75 10.06%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Nkarta Income Statement 2025-2011 | NKTX

Annual Income Statement Nkarta

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

158 M 145 M 636 M 164 M 504 M 1.03 B - - - - - - - - -

Shares

74 M 67.9 M 49 M 43.6 M 32.9 M 16.8 M - - - - - - - - -

Historical Prices

2.13 2.13 13 3.77 15.3 61.5 - - - - - - - - -

Net Income

-104 M -109 M -118 M -114 M -86.1 M -91.4 M -21.1 M -275 K - - - - - - -

Revenue

- - - - - - 115 K 6.55 M - - - - - - -

Operating Income

-122 M -128 M -132 M -119 M -86.4 M -51.5 M -22.3 M - - - - - - - -

Interest Expense

2.42 M 87 K 42 K -470 K -16 K -3 K 18 K - - - - - - - -

EBITDA

-113 M -119 M -126 M -116 M -84.6 M -50.7 M -21.9 M -173 K - - - - - - -

Operating Expenses

122 M 128 M 132 M 119 M 86.4 M 51.5 M 22.5 M 6.91 M - - - - - - -

General and Administrative Expenses

31.6 M 31.4 M 34.9 M 28.1 M 23 M 15.3 M 5.25 M 2.65 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement Nkarta

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

74.6 M 74.5 M 74.3 M 17.9 M 74 M 74 M 73.9 M 1.92 M 73.6 M 73.5 M 50.7 M 28.9 M 49.1 M 49 M 48.9 M 1.75 M 48.6 M 43.8 M 33 M 33.1 M 32.9 M 32.8 M 32.7 M 5.31 M 31 M 1.7 M 1.61 M 1.6 M 1.53 M 1.43 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-33.3 M -40.4 M -27.8 M -27.4 M -21.7 M -23 M -32 M -25.9 M -28.3 M -25 M -29.5 M -27.8 M -25.6 M -33.3 M -30.8 M -32.6 M -28.3 M -26.9 M -26 M -22.8 M -22.4 M -21.5 M -19.4 M -17.9 M -13.7 M -51.1 M -8.71 M - -2.67 M -4.84 M -3.08 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - 115 K 2.31 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-35.8 M -43.1 M -30.9 M -31 M -27.3 M -27.2 M -36.6 M -30.9 M -33.8 M -30.7 M -32.8 M -31.2 M -29.3 M -36.9 M -34.3 M -35 M -30.3 M -27.6 M -26.1 M -22.9 M -22.4 M -21.6 M -19.5 M -18 M -13.7 M -10.4 M -9.41 M - -5.91 M -4.67 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

206 K 222 K 206 K 256 K 1.72 M 239 K 205 K 94 K -3 K -2 K -2 K -25 K 33 K 1 K 33 K -489 K 17 K 3 K -1 K -2 K -6 K -5 K -2 K 146 K -153 K 4 K - - 35 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-33.7 M -40.4 M -28.5 M -28.7 M -25 M -24.9 M -34.3 M -28.6 M -31.4 M -28.5 M -30.5 M -28.9 M -27.3 M -36.1 M -33.5 M -34.3 M -29.6 M -27 M -25.5 M -22.3 M -21.9 M -21.2 M -19.2 M -17.7 M -13.5 M -10.3 M -9.31 M - -5.81 M -4.57 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

35.8 M 43.1 M 30.9 M 31 M 27.3 M 27.2 M 36.6 M 30.9 M 33.8 M 30.7 M 32.8 M 31.2 M 29.3 M 36.9 M 34.3 M 35 M 30.3 M 27.6 M 26.1 M 22.9 M 22.4 M 21.6 M 19.5 M 18 M 13.7 M 10.4 M 9.41 M - 5.91 M 4.67 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

6.31 M 14.1 M 5.89 M 5.68 M 7.09 M 6.41 M 12.4 M 7.8 M 8.54 M 7.58 M 7.52 M 7.86 M 7.1 M 11.7 M 8.18 M 8.14 M 6.83 M 6.56 M 6.53 M 5.59 M 5.81 M 5.68 M 5.94 M 6.73 M 3.92 M 2.49 M 2.15 M - 1.29 M 1.05 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Nkarta (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
$ 1.78 10.25 % $ 646 M usaUSA
Moleculin Biotech Moleculin Biotech
MBRX
$ 8.87 1.6 % $ 10.5 M usaUSA
Nurix Therapeutics Nurix Therapeutics
NRIX
$ 15.3 3.1 % $ 1.33 B usaUSA
MacroGenics MacroGenics
MGNX
$ 2.35 5.86 % $ 148 M usaUSA
Protagonist Therapeutics Protagonist Therapeutics
PTGX
$ 131.96 -2.54 % $ 8.39 B usaUSA
Nuvation Bio Nuvation Bio
NUVB
$ 4.15 -0.72 % $ 1.42 B usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
$ 40.36 0.21 % $ 179 B danmarkDanmark
Marker Therapeutics Marker Therapeutics
MRKR
$ 0.91 0.95 % $ 13.9 M usaUSA
NextCure NextCure
NXTC
$ 5.55 8.61 % $ 15.8 M usaUSA
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
$ 1.25 -1.57 % $ 65.7 M usaUSA
Olema Pharmaceuticals Olema Pharmaceuticals
OLMA
$ 7.32 8.21 % $ 637 M usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
$ 132.5 3.42 % $ 11.2 B usaUSA
Oragenics Oragenics
OGEN
$ 0.35 0.29 % $ 755 K usaUSA
Ovid Therapeutics Ovid Therapeutics
OVID
$ 2.86 10.66 % $ 372 M usaUSA
Passage Bio Passage Bio
PASG
$ 3.9 12.72 % $ 12.5 M usaUSA
Vaxcyte Vaxcyte
PCVX
$ 63.86 3.13 % $ 8.69 B usaUSA
Relay Therapeutics Relay Therapeutics
RLAY
$ 18.59 9.32 % $ 3.19 B usaUSA
Precigen Precigen
PGEN
$ 4.47 5.81 % $ 1.4 B usaUSA
Avidity Biosciences Avidity Biosciences
RNA
$ 8.36 0.48 % $ 1.15 B usaUSA
Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp.
PHIO
$ 0.8 -1.38 % $ 4.79 M usaUSA
Praxis Precision Medicines Praxis Precision Medicines
PRAX
$ 277.94 5.85 % $ 6.25 B usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
$ 3.59 0.98 % $ 276 M usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
$ 1.36 1.88 % $ 143 M niderlandNiderland
Ocular Therapeutix Ocular Therapeutix
OCUL
$ 6.61 2.8 % $ 1.24 B usaUSA
PolyPid Ltd. PolyPid Ltd.
PYPD
$ 6.08 7.23 % $ 99.4 M israelIsrael
Outlook Therapeutics Outlook Therapeutics
OTLK
$ 0.44 -0.93 % $ 15.3 M usaUSA
uniQure N.V. uniQure N.V.
QURE
$ 21.68 3.19 % $ 1.25 B niderlandNiderland
Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical
RARE
$ 15.48 -0.58 % $ 1.53 B usaUSA
Rafael Holdings Rafael Holdings
RFL
$ 1.02 -4.67 % $ 52.4 M usaUSA
REGENXBIO REGENXBIO
RGNX
$ 7.62 3.25 % $ 393 M usaUSA
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
$ 39.52 -13.54 % $ 711 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Tenax Therapeutics Tenax Therapeutics
TENX
$ 1.68 3.07 % $ 65.9 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 46.77 2.78 % $ 5.36 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Spero Therapeutics Spero Therapeutics
SPRO
$ 1.03 1.47 % $ 57.7 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Rezolute Rezolute
RZLT
$ 3.85 5.77 % $ 400 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 0.69 11.43 % $ 73.6 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina